- Cancer Antibodies
- Metabolism Antibodies
- New Antibodies
- Crown Antibodies
- Secondary Antibodies >
- Stem Cells
- Neurodegeneration >
- Goat Antibodies
- GPCR Antibodies
- Infectious Disease and Small Molecules
- Loading Control Antibodies
- Tag Antibody
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Biological Process >
- FL cDNA Clones
RNF43 Antibody (C-term)
Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
United StatesOrdering Information
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanKoreaLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamOthers
(40 western blots)
|In Stock||$ 265.00||DISCONTINUED INQUIRE CLICK INQUIRE Add to cart|
(8 western blots)
|In Stock||$ 95.00||DISCONTINED INQUIRE CLICK INQUIRE Add to cart|
- Citations : 0
RNF43 Antibody (C-term) - Product Information
|Application ||WB, IHC|
|Antigen Region||543-572 aa|
RNF43 Antibody (C-term) - Additional Information
|Gene ID 54894|
E3 ubiquitin-protein ligase RNF43, 632-, RING finger protein 43, RNF43
This RNF43 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 543-572 amino acids from the C-terminal region of human RNF43.
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
RNF43 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.
RNF43 Antibody (C-term) - Protein Information
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signaling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled. Acts on both canonical and non-canonical Wnt signaling pathway. Acts as a tumor suppressor in the intestinal stem cell zone by inhibiting the Wnt signaling pathway, thereby resticting the size of the intestinal stem cell zone.
Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Nucleus envelope. Note=According to a report, may be secreted.
Expressed in fetal kidney, fetal lung, in colon cancer tissues, hepatocellular carcinomas and lung adenocarcinomas. Overexpressed in colorectal cancer cell lines
RNF43 Antibody (C-term) - Related Products
RNF43 Antibody (C-term) - Research Areas
RNF43 Antibody (C-term) (Cat. #AP13204b) western blot analysis in CEM cell line lysates (35ug/lane).This demonstrates the RNF43 antibody detected the RNF43 protein (arrow).
RNF43 Antibody (C-term) (Cat. #AP13204b)immunohistochemistry analysis in formalin fixed and paraffin embedded human kidney tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of RNF43 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
RNF43 is a HAP95 (AKAP8L; MIM 609475) binding ubiquitin ligase that promotes cell growth and is upregulated in colon cancer (Yagyu et al., 2004 [PubMed 15492824]; Sugiura et al., 2008 [PubMed 18313049]).
Low, S.K., et al. PLoS ONE 5 (7), E11824 (2010) :
Sugiura, T., et al. Exp. Cell Res. 314(7):1519-1528(2008)
Uchida, N., et al. Clin. Cancer Res. 10(24):8577-8586(2004)
Yagyu, R., et al. Int. J. Oncol. 25(5):1343-1348(2004)